165 related articles for article (PubMed ID: 35486030)
41. Rapid Capture of Cancer Extracellular Vesicles by Lipid Patch Microarrays.
Liu HY; Kumar R; Zhong C; Gorji S; Paniushkina L; Masood R; Wittel UA; Fuchs H; Nazarenko I; Hirtz M
Adv Mater; 2021 Sep; 33(35):e2008493. PubMed ID: 34309083
[TBL] [Abstract][Full Text] [Related]
42. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
Goss KL; Gordon DJ
Oncotarget; 2016 Sep; 7(39):63003-63019. PubMed ID: 27557498
[TBL] [Abstract][Full Text] [Related]
43. Regulation of FAS exon definition and apoptosis by the Ewing sarcoma protein.
Paronetto MP; Bernardis I; Volpe E; Bechara E; Sebestyén E; Eyras E; Valcárcel J
Cell Rep; 2014 May; 7(4):1211-26. PubMed ID: 24813895
[TBL] [Abstract][Full Text] [Related]
44. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.
Niedan S; Kauer M; Aryee DN; Kofler R; Schwentner R; Meier A; Pötschger U; Kontny U; Kovar H
Oncogene; 2014 Jul; 33(30):3927-38. PubMed ID: 23995784
[TBL] [Abstract][Full Text] [Related]
45. PRAS40 is a functionally critical target for EWS repression in Ewing sarcoma.
Huang L; Nakai Y; Kuwahara I; Matsumoto K
Cancer Res; 2012 Mar; 72(5):1260-9. PubMed ID: 22241085
[TBL] [Abstract][Full Text] [Related]
46. Ewing sarcoma EWS protein regulates midzone formation by recruiting Aurora B kinase to the midzone.
Park H; Turkalo TK; Nelson K; Folmsbee SS; Robb C; Roper B; Azuma M
Cell Cycle; 2014; 13(15):2391-9. PubMed ID: 25483190
[TBL] [Abstract][Full Text] [Related]
47. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.
Sankar S; Theisen ER; Bearss J; Mulvihill T; Hoffman LM; Sorna V; Beckerle MC; Sharma S; Lessnick SL
Clin Cancer Res; 2014 Sep; 20(17):4584-97. PubMed ID: 24963049
[TBL] [Abstract][Full Text] [Related]
48. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.
Lee HJ; Yoon C; Schmidt B; Park DJ; Zhang AY; Erkizan HV; Toretsky JA; Kirsch DG; Yoon SS
Mol Cancer Ther; 2013 Nov; 12(11):2591-600. PubMed ID: 23966622
[TBL] [Abstract][Full Text] [Related]
49. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
[TBL] [Abstract][Full Text] [Related]
50. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ
J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923
[TBL] [Abstract][Full Text] [Related]
51. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
52. The role of miR-17-92 in the miRegulatory landscape of Ewing sarcoma.
Schwentner R; Herrero-Martin D; Kauer MO; Mutz CN; Katschnig AM; Sienski G; Alonso J; Aryee DN; Kovar H
Oncotarget; 2017 Feb; 8(7):10980-10993. PubMed ID: 28030800
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.
Hong SH; Youbi SE; Hong SP; Kallakury B; Monroe P; Erkizan HV; Barber-Rotenberg JS; Houghton P; Üren A; Toretsky JA
Oncotarget; 2014 Jan; 5(2):338-50. PubMed ID: 24481407
[TBL] [Abstract][Full Text] [Related]
54. ALK-Fusion Transcripts Can Be Detected in Extracellular Vesicles (EVs) from Nonsmall Cell Lung Cancer Cell Lines and Patient Plasma: Toward EV-Based Noninvasive Testing.
Sánchez-Herrero E; Campos-Silva C; Cáceres-Martell Y; Robado de Lope L; Sanz-Moreno S; Serna-Blasco R; Rodríguez-Festa A; Ares Trotta D; Martín-Acosta P; Patiño C; Coronado MJ; Beneitez A; Jara R; Lago-Baameiro N; Camino T; Cruz-Bermúdez A; Pardo M; González-Rumayor V; Valés-Gómez M; Provencio M; Romero A
Clin Chem; 2022 May; 68(5):668-679. PubMed ID: 35348673
[TBL] [Abstract][Full Text] [Related]
55. A Druggable Rheostat for Ewing Sarcoma?
Weiss KR; Bailey KM
Clin Cancer Res; 2022 Oct; 28(20):4360-4362. PubMed ID: 35921177
[TBL] [Abstract][Full Text] [Related]
56. Extracellular vesicles on demand (EVOD) chip for screening and quantification of cancer-associated extracellular vesicles.
Kang YT; Hadlock T; Jolly S; Nagrath S
Biosens Bioelectron; 2020 Nov; 168():112535. PubMed ID: 32871498
[TBL] [Abstract][Full Text] [Related]
57. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.
Kovar H; Amatruda J; Brunet E; Burdach S; Cidre-Aranaz F; de Alava E; Dirksen U; van der Ent W; Grohar P; Grünewald TG; Helman L; Houghton P; Iljin K; Korsching E; Ladanyi M; Lawlor E; Lessnick S; Ludwig J; Meltzer P; Metzler M; Mora J; Moriggl R; Nakamura T; Papamarkou T; Radic Sarikas B; Rédini F; Richter GH; Rossig C; Schadler K; Schäfer BW; Scotlandi K; Sheffield NC; Shelat A; Snaar-Jagalska E; Sorensen P; Stegmaier K; Stewart E; Sweet-Cordero A; Szuhai K; Tirado OM; Tirode F; Toretsky J; Tsafou K; Üren A; Zinovyev A; Delattre O
Oncotarget; 2016 Feb; 7(8):8613-24. PubMed ID: 26802024
[TBL] [Abstract][Full Text] [Related]
58. DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1-NFATc2 fusion from Ewing sarcoma.
Koelsche C; Kriegsmann M; Kommoss FKF; Stichel D; Kriegsmann K; Vokuhl C; Grünewald TGP; Romero-Pérez L; Kirchner T; de Alava E; Diaz-Martin J; Hartmann W; Baumhoer D; Antonescu CR; Szuhai K; Flucke U; Dirksen U; Pfister SM; Jones DTW; Mechtersheimer G; von Deimling A
J Cancer Res Clin Oncol; 2019 May; 145(5):1273-1281. PubMed ID: 30895378
[TBL] [Abstract][Full Text] [Related]
59. Single-step RT-qPCR for detection of extracellular vesicle microRNAs in vivo: a time- and cost-effective method.
Lee H; He X; Le T; Carnino JM; Jin Y
Am J Physiol Lung Cell Mol Physiol; 2020 Apr; 318(4):L742-L749. PubMed ID: 32073880
[TBL] [Abstract][Full Text] [Related]
60. Modeling the initiation of Ewing sarcoma tumorigenesis in differentiating human embryonic stem cells.
Gordon DJ; Motwani M; Pellman D
Oncogene; 2016 Jun; 35(24):3092-102. PubMed ID: 26455317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
